The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, 4D Molecular Therapeutics's share price is $25.70.
4D Molecular Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.49. Hence, 4D Molecular Therapeutics's PS Ratio for today is 52.13.
The historical rank and industry rank for 4D Molecular Therapeutics's PS Ratio or its related term are showing as below:
FDMT'
s PS Ratio Range Over the Past 10 Years
Min: 10.01 Med: 53.51 Max: 383.61
Current: 52.13
During the past 7 years, 4D Molecular Therapeutics's highest PS Ratio was 383.61. The lowest was 10.01. And the median was 53.51.
FDMT's PS Ratio is ranked worse than 79.6% of 1000
companies
in the Biotechnology industry
Industry Median: 9.095
vs FDMT: 52.13
During the past 7 years, 4D Molecular Therapeutics's highest 3-Year average Revenue per Share Growth Rate was 75.70% per year. The lowest was -40.90% per year. And the median was -26.90% per year.
Back to Basics: PS Ratio
4D Molecular Therapeutics PS Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of 4D Molecular Therapeutics's PS Ratio
For the Biotechnology subindustry, 4D Molecular Therapeutics's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
4D Molecular Therapeutics's PS Ratio Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, 4D Molecular Therapeutics's PS Ratio distribution charts can be found below:
* The bar in red indicates where 4D Molecular Therapeutics's PS Ratio falls into.
4D Molecular Therapeutics PS Ratio Calculation
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
4D Molecular Therapeutics's Share Price of today is $25.70. 4D Molecular Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.49.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
4D Molecular Therapeutics (NAS:FDMT) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
4D Molecular Therapeutics PS Ratio Related Terms
Thank you for viewing the detailed overview of 4D Molecular Therapeutics's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
4D Molecular Therapeutics (4D Molecular Therapeutics) Business Description
4D Molecular Therapeutics Inc a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built portfolio of gene therapy product candidates focused in three therapeutic areas: ophthalmology (intravitreal vector), cardiology (intravenous vector) and pulmonology (aerosol vector). It has three product candidates in clinical trials: 4D-125 for the treatment of X-linked retinitis pigmentosa in a Phase 1/2 clinical trial, 4D-110 for the treatment of choroideremia in a Phase 1 clinical trial, and 4D-310 for the treatment of Fabry disease in a Phase 1/2 clinical trial. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration, and 4D-710 for the treatment of cystic fibrosis lung disease.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FDMT has been successfully added to your 